This poster is published under an
open license. Please read the
disclaimer for further details.
Keywords:
Oncology, Professional issues, CT, PACS, RIS, Health policy and practice, Outcomes analysis, Structured reporting, Cancer, Outcomes, Education and training
Authors:
D. J. Vining, R. Kampalath, R. Bassett, P. Fox, A. Tsimberidou; Houston, TX/US
DOI:
10.1594/ecr2014/C-2138
Aims and objectives
Tumor response to anticancer therapy is frequently determined by a change in the cumulative sizes of target lesions as measured on serial imaging examinations.
Formal measurement of tumors began in 1979 with the World Health Organization’s criteria employing bi-dimensional measurements (1).
In 2000,
the Response Evaluation Criteria In Solid Tumors (RECIST) criteria emerged to simplify tumor assessment with uni-dimensional measurements of selected target lesions,
and this was later refined in 2009 with a reduction in the number of required target lesions as well as guidance for the measurement of lymph nodes (2,
3).
The purpose of our study was to evaluate if radiologists at the University of Texas MD Anderson Cancer Center,
a National Cancer Institute-designated cancer center,
consistently measured and reported on tumors from serial examinations which is critical for the application of RECIST,
especially for patients enrolled in clinical trials.